1 roundtable forum, 1 analyst and 15 sector firms examine the Biotechnology segment in this 107-page report from The Wall Street Transcript.
Order this Report
Roundtable Forum - Investing in Biotechnology Stocks: George Huang, Stansberry & Associates; Dr. Raghuram Selvaraju, Hapoalim Securities USA, Inc.; Steven Silver, Standard & Poor's Equity Research
Biotechnology Companies: Carol Werther, Summer Street Research Partners
Off the Record: Off the Record asks company leadership which management teams in their sector they most respect for their ability to execute and generate shareholder value.
CEO Interviews (average 2,500 words): Top management from 15 sector firms examine the outlook for their firm and sector. Firms interviewed include: Advaxis, Inc., Labopharm Inc., NeoStem, Inc., Polydex Pharmaceuticals Limited, Aeterna Zentaris Inc., Urigen Pharmaceuticals, Inc., AcquiSci Inc., Genmed Holding Corp., MDRNA, Inc., Nuvilex, Inc., Nuvo Research Inc., Ondine Biopharma Corporation, PURE Bioscience, WEX Pharmaceuticals, Inc., XOMA Ltd.
Topics covered: Negative financing environment - Regulatory outlook - R&D spending outlook - M&A activity - Potential acquisition targets - Big Pharma interest in acquisitions - FDA approval process - Missed PDUFA dates - Molecular diagnostics growth area - Follow-on biologics - Activist shareholder action - Cost containment measures - More generic drug usage - IPO window - Shortage of cash - Expectation of more bankruptcies - Winners and losers - Investor interest - Stocks picks
ORDER THIS REPORT NOW! CLICK HERE
Companies covered: Genzyme (GENZ); Celgene (CELG); Gilead Sciences (GILD); Medivation (MDVN); Sequenom (SQNM); XenoPort (XNPT); ARYx Therapeutics (ARYX); Biogen Idec (BIIB); Dendreon (DNDN); Acorda Therapeutics (ACOR); Alexion (ALXN); Cardiome (CRME); Vertex Pharmaceuticals (VRTX); Avigen (AVGN); Amylin Pharmaceuticals (AMLN); Micromet (MITI); BioMarin Pharmaceuticals (BMRN); Myriad Genetics (MYGN).
